CD47 and diffuse large B-cell lymphoma: The ORR reported in this trial (59.3%) was comparable to that reported for most regimens used in transplantation‐ineligible R/R DLBCL patients, including mosunetuzumab plus polatuzumab vedotin (59.2%) [37], tafasitamab plus lenalidomide (60.0%) [38], and magrolimab (an anti‐CD47 antibody) plus R‐GemOx (51.5%) [39], but higher than that reported for the R‐Gemox group (40.7%) [40].